Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on August 10, 2016. The filing addresses corporate governance changes, specifically the resignation of a director and the election of a new Chairman of the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of Director: Dr. M. James Barrett, Ph.D., resigned from the Board of Directors effective immediately on August 10, 2016. He had served as Chairman of the Board since 2005, as well as Chairman of the Compensation Committee and a member of the Governance and Nominating Committee.
- Reason for Resignation: The resignation aligns with New Enterprise Associates' (NEA) exit from the company and Dr. Barrett's need to focus on other board positions within the NEA portfolio.
- Election of New Chairman: The Board unanimously elected Charles W. Newhall, III, a current independent director, as the new Chairman. Mr. Newhall has served on the Board since 2005 and currently chairs the Governance and Nominating Committee.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, or specific risk factors. The primary contingency noted is the leadership transition at the board level.
Investor Verification Checklist
- Verify the effective date of Dr. Barrett's resignation and the immediate assumption of duties by Mr. Newhall.
- Confirm the updated composition of the Board of Directors and committee assignments following the transition.
- Review the attached Press Release (Exhibit 99.1) for additional context on the leadership change.
- Note that this filing does not impact the company's financial statements or operational metrics.